

# FORM: Preliminary final report

Name of *issuer*

**Beroni Group Limited**

ACN or ARBN

606 066 059

Half yearly  
(tick)

☐

Preliminary  
final (tick)

☒

Half year/financial year ended  
(‘Current period’)

Financial year ended 31  
December 2018

## For announcement to the market

Extracts from this statement for announcement to the market (*see note 1*).

Extracts from this statement for announcement to the market (see note 17).

				\$A,000
Revenue (item 1.1)	Down	8.6%	to	2,447
Profit (loss) for the period (item 1.9)	Down	245.7%	to	(2,506)
Profit (loss) for the period attributable to members of the parent (item 1.11)	Down	234.9%	to	(2,429)
<b>Dividends</b>	Current period		Previous corresponding period	
Franking rate applicable:	-		-	
<b>Final dividend</b> (preliminary final report only) (item 10.13-10.14)	-		-	
Amount per security				
Franked amount per security				
<b>Interim dividend</b> (Half yearly report only) (item 10.11 – 10.12)	-		-	
Amount per security				
Franked amount per security				
Short details of any bonus or cash issue or other item(s) of importance not previously released to the market:				
N/A				

**Consolidated income statement** *(The figures are not equity accounted)**(see note 3)**(as per paragraphs 81-85 and 88-94 of AASB 101: Presentation of Financial Statements)*

	Current period - \$A'000	Previous corresponding period - \$A'000
1.1 Revenues <i>(item 7.1)</i>	2,446	2,676
1.2 Expenses, excluding finance costs <i>(item 7.2)</i>	5,044	3,282
1.3 Finance costs	2	17
1.4 Share of net profits (losses) of associates and joint ventures <i>(item 15.7)</i>	-	-
1.5 <b>Profit (loss) before income tax</b>	(2,600)	(623)
1.6 Income tax expense <i>(see note 4)</i>	(94)	102
1.7 Profit (loss) from continuing operations	-	-
1.8 Profit (loss) from discontinued operations <i>(item 13.3)</i>	-	-
1.9 <b>Profit (loss) for the period</b>	(2,506)	(725)
1.10 Profit (loss) attributable to minority interests	(78)	-
1.11 <b>Profit (loss) attributable to members of the parent</b>	(2,428)	(725)
1.12 Basic earnings per <i>security</i> <i>(item 9.1)</i>	(3.82)	(1.40)
1.13 Diluted earnings per <i>security</i> <i>(item 9.1)</i>	(3.82)	(1.40)
1.14 Dividends per <i>security</i> <i>(item 9.1)</i>	-	-

**Comparison of half-year profits***(Preliminary final statement only)*

	Current period - \$A'000	Previous corresponding period - \$A'000
2.1 Consolidated profit (loss) after tax attributable to members reported for the 1st half year <i>(item 1.11 in the half yearly statement)</i>	(1,666)	65
2.2 Consolidated profit (loss) after tax attributable to members for the 2nd half year	(762)	(790)

## Consolidated balance sheet

(See note 5)

(as per paragraphs 68-69 of AASB 101: Financial Statement Presentation)

<b>Current assets</b>		Current period - \$A'000	Previous corresponding period - \$A'000
3.1	Cash and cash equivalents	5,748	8,670
3.2	Trade and other receivables	2,796	1,743
3.3	Inventories	48	163
3.4	Prepayments	4,427	476
3.5	<b>Total current assets</b>	13,019	11,052
<b>Non-current assets</b>			
3.6	Available for sale investments	-	-
3.7	Other financial assets	-	-
3.8	Investments in other entities	3,656	-
3.9	Deferred tax assets	129	47
3.10	Exploration and evaluation expenditure capitalised (see para. 71 of AASB 1022 – new standard not yet finalised)	-	-
3.11	Development properties (mining entities)	-	-
3.12	Property, plant and equipment (net)	210	153
3.13	Investment properties	-	-
3.14	Goodwill	-	-
3.15	Other intangible assets	1,337	-
3.16	Other (provide details if material)	282	48
3.17	<b>Total non-current assets</b>	5,614	248
3.18	<b>Total assets</b>	18,633	11,300
<b>Current liabilities</b>			
3.19	Trade and other payables	272	229
3.20	Short term borrowings	-	-
3.21	Current tax payable	23	93
3.22	Short term provisions	-	-
3.23	Current portion of long term borrowings	-	-
3.24	Other current liabilities (provide details if material)	93	162
		388	484
3.25	Liabilities directly associated with non-current assets classified as held for sale (para 38 of AASB 5)	-	-
3.26	<b>Total current liabilities</b>	388	484
<b>Non-current liabilities</b>			

		Current period - \$A'000	Previous corresponding period - \$A'000
3.27	Long-term borrowings	-	-
3.28	Deferred tax liabilities	-	-
3.29	Long term provisions	-	-
3.30	Other (provide details if material)	-	-
3.31	<b>Total non-current liabilities</b>	-	-
3.32	<b>Total liabilities</b>	388	484
3.33	<b>Net assets</b>	18,245	10,816
	<b>Equity</b>		
3.34	Share capital	20,913	11,372
3.35	Other reserves	291	(8)
3.36	Retained earnings	(2,913)	(548)
	Amounts recognised directly in equity relating to non-current assets classified as held for sale		
3.37	<b>Parent interest</b>	18,291	-
3.38	<b>Minority interest</b>	(46)	-
3.39	<b>Total equity</b>	18,245	10,816

## Consolidated statement of changes in equity

(as per paragraphs 96-97 of AASB 101: Presentation of Financial Statements)

	Current period – A\$'000	Previous corresponding period – A\$'000
Revenues recognised directly in equity:	-	-
Expenses recognised directly in equity:	-	-
4.1 <b>Net income recognised directly in equity</b>	-	-
4.2 <b>Profit for the period</b>	(2,506)	(725)
4.3 <b>Total recognised income and expense for the period</b>		
Attributable to:		
4.4 Members of the parent	(2,429)	(725)
4.5 Minority interest	(77)	-
Effect of changes in accounting policy (as per AASB 108: Accounting Policies, Changes in Accounting Estimates and Errors):		
4.6 Members of the parent entity	-	-
4.7 Minority interest	-	-

## Consolidated statement of cash flows

(See note 6)

(as per AASB 107: Cash Flow Statements)

		Current period - \$A'000	Previous corresponding period - \$A'000
	<b>Cash flows related to operating activities</b>		
5.1	Receipts from customers	2,012	2,013
5.2	Payments to suppliers and employees	(5,482)	(4,087)
5.3	Interest and other costs of finance paid	-	(17)
5.4	Income taxes paid	(74)	(73)
5.5	Other – receipts from government	-	366
5.6	<b>Net cash generated from/(used in) operating activities</b>	(3,544)	(1,798)
	<b>Cash flows related to investing activities</b>		
5.7	Payments for purchases of property, plant and equipment	(250)	(25)
5.8	Proceeds from sale of property, plant and equipment	15	-
5.9	Payment for purchases of intangible assets	(1,336)	-
5.10	Proceeds from sale of equity investments	-	-
5.11	Loans to other entities	-	-
5.12	Prepayment for investment in Cystemix	(550)	-
5.13	Investment in other entities	(3,656)	-
5.14	Interest and other items of similar nature received	36	19
5.15	Dividends received	-	-
5.16	Other (provide details if material)	(41)	(1)
5.17	<b>Net cash used in investing activities</b>	(5,782)	(7)
	<b>Cash flows related to financing activities</b>		
5.18	Proceeds from issues of securities (shares, options, etc.)	5,952	7,832
5.19	Proceeds from borrowings	203	197
5.20	Repayment of borrowings	-	-
5.21	Dividends paid	-	-
5.22	Other (provide details if material)	-	-
5.23	<b>Net cash provided by financing activities</b>	6,155	8,029
	<b>Net increase in cash and cash equivalents</b>	(3,171)	6,224
5.24	Cash at beginning of period (see <i>Reconciliations of cash</i> )	8,669	2,252
5.25	Exchange rate adjustments to item 5.23	249	193
5.26	<b>Cash at end of period</b> (see <i>Reconciliation of cash</i> )	5,747	8,669

## Reconciliation of cash provided by operating activities to profit or loss

(as per paragraph Aus20.1 of AASB 107: Cash Flow Statements)

	Current period \$A'000	Previous corresponding period \$A'000
6.1 <b>Profit</b> <i>(item 1.9)</i>	(2,506)	(725)
Adjustments for non-cash items:		
6.2 Depreciation & amortisation	85	48
6.3 Foreign exchange impact	(206)	13
Movements in assets and liabilities:		
6.6 Increase/decrease in receivables	(1,135)	26
6.7 Increase/decrease in prepayments	217	(229)
6.8 Increase/decrease in inventory	115	(73)
6.9 Increase/decrease in payables	25	(1,075)
6.10 Increase/decrease in other liabilities	(139)	220
6.11 <b>Net cash from operating activities</b> <i>(item 5.6)</i>	(3,544)	(1,795)

## **Notes to the financial statements**

### **Details of revenues and expenses**

(see note 16)

(Where items of income and expense are material, disclose nature and amount below in accordance with paragraphs 86-87 of AASB 101: Presentation of Financial Statements)

	Current period - \$A'000	Previous corresponding period - \$A'000
Revenue		
Services and commissions	2,164	2,291
Interest	36	19
Government subsidies	219	366
Others	27	-
7.1 Total Revenue	2,446	2,676
Expenses		
Wages and salaries	568	385
Depreciation and amortisation	85	48
Rental	65	257
IPO & dual listing expenses	606	723
Others	3,720	1,869
7.2 Total Expenses	5,044	3,282
Profit (loss) before tax	(2,600)	(623)

### **Ratios**

	Current period	Previous corresponding period
<b>Profit before tax / revenue</b>		
8.1 Consolidated profit (loss) before tax (item 1.5) as a percentage of revenue (item 1.1)	(106.3%)	(23.3%)
<b>Profit after tax / equity interests</b>		
8.2 Consolidated profit (loss) after tax attributable to members (item 1.11) as a percentage of equity (similarly attributable) at the end of the period (item 3.37)	(13.3%)	(6.7%)



## Earnings per Security

- 9.1 Provide details of basic and fully diluted EPS in accordance with paragraph 70 and Aus 70.1 of AASB 133: Earnings per Share below:

Basic earnings per share amounts are calculated by dividing profit after income tax by the weighted average number of ordinary shares outstanding during the year.

Diluted earnings per share amounts are calculated by dividing profit after income tax by the weighted average number of ordinary share outstanding during the year (adjusted for the effects of any dilutive options or preference shares).

The following reflects the income and share data used in the basic and diluted earnings per share computations;

Profit (loss) after income tax expense	(\$2,506,373)	N/A
Weighted average number of ordinary shares for basic and diluted earnings per share	65,537,908	N/A

## Dividends

- 10.1 Date the dividend is payable

N/A

- 10.2 Record date to determine entitlements to the dividend (i.e. on the basis of registrable transfers received up to 5.00 pm if paper based, or by 'End of Day' if a proper ASTC/CHESS transfer)

N/A

- 10.3 If it is a final dividend, has it been declared? N/A

(Preliminary final report only)

- 10.4 The *dividend or distribution plans* shown below are in operation.

N/A

The last date(s) for receipt of election notices to the *dividend or distribution plans*

N/A

- 10.5 Any other disclosures in relation to *dividends or distributions*

N/A

**Dividends paid or provided for on all securities***(as per paragraph Aus126.4 AASB 101: Presentation of Financial Statements)*

	Current period - \$A'000	Previous corresponding period - \$A'000	Franking rate applicable
<b>Dividends paid or provided for during the reporting period</b>			
10.6 Current year interim	-	-	-
10.7 Franked dividends	-	-	-
10.8 Previous year final	-	-	-
10.9 Franked dividends	-	-	-
<b>Dividends proposed and not recognised as a liability</b>			
10.10 Franked dividends			-

**Dividends per security***(as per paragraph Aus126.4 of AASB 101: Presentation of Financial Statements)*

	Current year	Previous year	Franking rate applicable
<b>Dividends paid or provided for during the reporting period</b>			
10.11 Current year interim	-	-	-
10.12 Franked dividends – cents per share	-	-	-
10.13 Previous year final	-	-	-
10.14 Franked dividends – cents per share	-	-	-
<b>Dividends proposed and not recognised as a liability</b>			
10.15 Franked dividends – cents per share	-	-	-

**Exploration and evaluation expenditure capitalised**

*To be completed only by issuers with mining interests if amounts are material. Include all expenditure incurred regardless of whether written off directly against profit*

		Current period \$A'000	Previous corresponding period \$A'000
11.1	Opening balance	-	-
11.2	Expenditure incurred during current period	-	-
11.3	Expenditure written off during current period	-	-
11.4	Acquisitions, disposals, revaluation increments, etc.	-	-
11.5	Expenditure transferred to Development Properties	-	-
11.6	<b>Closing balance as shown in the consolidated balance sheet (item 3.10)</b>	-	-

**Development properties**

*(To be completed only by issuers with mining interests if amounts are material)*

		Current period \$A'000	Previous corresponding period \$A'000
12.1	Opening balance	-	-
12.2	Expenditure incurred during current period	-	-
12.3	Expenditure transferred from exploration and evaluation	-	-
12.4	Expenditure written off during current period	-	-
12.5	Acquisitions, disposals, revaluation increments, etc.	-	-
12.6	Expenditure transferred to mine properties	-	-
12.7	<b>Closing balance as shown in the consolidated balance sheet (item 3.11)</b>	-	-

**Discontinued Operations**

*(see note 18)*

*(as per paragraph 33 of AASB 5: Non-current Assets Held for Sale and Discontinued Operations)*

		Current period – A\$'000	Previous corresponding period – A\$'000
13.1	Revenue	-	-
13.2	Expense	-	-
13.3	<b>Profit (loss) from discontinued operations before income tax</b>	-	-
13.4	Income tax expense <i>(as per para 81 (h) of AASB 112)</i>	-	-
13.5	<b>Gain (loss) on sale/disposal of discontinued operations</b>	-	-
13.6	Income tax expense <i>(as per paragraph 81(h) of AASB 112)</i>	-	-

## Movements in Equity

(as per paragraph 97 of AASB 101: Financial Statement Presentation)

		Number issued	Number listed	Paid-up value (cents)	Current period – A\$'000	Previous corresponding period – A\$'000
14.1	<b>Preference securities</b> <i>(description)</i>	-	-	-	-	-
14.2	Balance at start of period	-	-	-	-	-
14.3	a) Increases through issues	-	-	-	-	-
14.4	a) Decreases through returns of capital, buybacks etc.	-	-	-	-	-
14.5	Balance at end of period	-	-	-	-	-
14.6	<b>Ordinary securities</b> <i>(description)</i>	-	-	-	-	-
14.7	Balance at start of period	60,177,683	60,177,683	-	11,372	2,107
14.8	a) Increases through issues	9,924,665	9,924,665	-	9,541	9,265
14.9	b) Decreases through returns of capital, buybacks etc.	-	-	-	-	-
14.10	Balance at end of period	70,102,348	70,102,348	-	20,913	11,372
14.11	<b>Convertible Debt Securities</b> <i>(description &amp; conversion factor)</i>	-	-	-	-	-
14.12	Balance at start of period	-	-	-	-	-
14.13	a) Increases through issues	-	-	-	-	-
14.14	b) Decreases through maturity, converted.	-	-	-	-	-
14.15	Balance at end of period	-	-	-	-	-

		<b>Number issued</b>	<b>Number listed</b>	<b>Paid-up value (cents)</b>	<b>Current period – A\$'000</b>	<b>Previous corresponding period – A\$'000</b>
14.16	<b>Options</b>  <i>(description &amp; conversion factor)</i>	-	-	-	-	-
14.17	Balance at start of period	-	-	-	-	-
14.18	Issued during period	-	-	-	-	-
14.19	Exercised during period	-	-	-	-	-
14.20	Expired during period	-	-	-	-	-
14.21	Balance at end of period	-	-	-	-	-
14.22	<b>Debentures</b>  <i>(description)</i>	-	-	-	-	-
14.23	Balance at start of period	-	-	-	-	-
14.24	a) Increases through issues	-	-	-	-	-
14.25	b) Decreases through maturity, converted	-	-	-	-	-
14.26	Balance at end of period	-	-	-	-	-
14.27	<b>Unsecured Notes</b>  <i>(description)</i>	-	-	-	-	-
14.28	Balance at start of period	-	-	-	-	-
14.29	a) Increases through issues	-	-	-	-	-
14.30	b) Decreases through maturity, converted	-	-	-	-	-
14.31	Balance at end of period	-	-	-	-	-
14.32	<b>Total Securities</b>	-	-	-	-	-

		Current period – A\$'000	Previous corresponding period – A\$'000
<b>Reserves</b>			
14.33	Balance at start of period	8	(130)
14.34	Transfers to/from reserves	282	122
14.35	Total for the period	282	122
14.36	Balance at end of period	290	(8)
14.37	<b>Total reserves</b>	290	(8)
<b>Retained earnings</b>			
14.38	<b>Balance at start of period</b>	(565)	177
14.39	Changes in accounting policy	-	-
14.40	Restated balance	-	-
14.41	Profit for the balance	-	-
14.42	Total for the period	(2,347)	(725)
14.43	Dividends	-	-
14.44	<b>Balance at end of period</b>	(2,912)	(548)

## Details of aggregate share of profits (losses) of associates and joint venture entities

(equity method)

(as per paragraph Aus 37.1 of AASB 128: Investments in Associates and paragraph Aus 57.3 of AASB 131: Interests in Joint Ventures)

Name of associate or joint venture entity

N/A

Reporting entities percentage holding

N/A

		Current period - \$A'000	Previous corresponding period - \$A'000
15.1	Profit (loss) before income tax	-	-
15.2	Income tax	-	-
15.3	<b>Profit (loss) after tax</b>	-	-
15.4	Impairment losses	-	-
15.5	Reversals of impairment losses	-	-
15.6	Share of non-capital expenditure contracted for (excluding the supply of inventories)	-	-
15.7	<b>Share of net profit (loss) of associates and joint venture entities</b>	-	-

## Control gained over entities having material effect

(See note 8)

16.1 Name of *issuer* (or *group*)

N/A

	\$A'000
16.2 Consolidated profit (loss) after tax of the <i>issuer</i> (or <i>group</i> ) since the date in the current period on which control was acquired	-
16.3 Date from which profit (loss) in <i>item 16.2</i> has been calculated	-
16.4 Profit (loss) after tax of the <i>issuer</i> (or <i>group</i> ) for the whole of the previous corresponding period	-

**Loss of control of entities having material effect***(See note 8)*

17.1	Name of <i>issuer</i> (or <i>group</i> )	N/A
17.2	Consolidated profit (loss) after tax of the entity (or <i>group</i> ) for the current period to the date of loss of control	\$A'000 -
17.3	Date from which the profit (loss) in <i>item 17.2</i> has been calculated	-
17.4	Consolidated profit (loss) after tax of the entity (or <i>group</i> ) while controlled during the whole of the previous corresponding period	-
17.5	Contribution to consolidated profit (loss) from sale of interest leading to loss of control	-

**Material interests in entities which are not controlled entities***The economic entity has an interest (that is material to it) in the following entities.*

		Percentage of ownership interest (ordinary securities, units etc) held at end of period or date of disposal		Contribution to profit (loss) ( <i>item 1.9</i> )	
18.1	Equity accounted associated entities	Current period	Previous corresponding period	Current period \$A'000	Previous corresponding period \$A'000
				<i>Equity accounted</i>	
		-	-	-	-
18.2	<b>Total</b>	-	-	-	-
18.3	<b>Other material interests</b>			Non equity accounted (i.e. part of <i>item 1.9</i> )	
		-	-	-	-
18.4	<b>Total</b>	-	-	-	-



## Reports for industry and geographical segments

Information on the industry and geographical segments of the entity must be reported for the current period in accordance with AASB 114: Segment Reporting. Because of the different structures employed by entities, a pro forma is not provided. Segment information should be completed separately and attached to this statement. However, the following is the presentation adopted in the Appendices to AASB 114 and indicates which amount should agree with items included elsewhere in this statement.

	Current period - \$A'000	Previous corresponding period - \$A'000
<b>Segments</b>	-	-
Revenue:		
19.1 External sales		
19.2 Inter-segment sales		
19.3 <b>Total</b> (consolidated total equal to <i>item 1.1</i> )	-	-
19.4 Segment result		
19.5 Unallocated expenses		
19.6 <b>Operating profit</b> (equal to <i>item 1.5</i> )	-	-
19.7 Interest expense		
19.8 Interest income		
19.9 Share of profits of associates		
19.10 Income tax expense		
19.11 <b>Net profit</b> (consolidated total equal to <i>item 1.9</i> )	-	-
<b>Other information</b>		
19.12 Segment assets		
19.13 Investments in equity method associates		
19.14 Unallocated assets		
19.15 <b>Total assets</b> (equal to <i>item 3.18</i> )	-	-
19.16 Segment liabilities		
19.17 Unallocated liabilities		
19.18 <b>Total liabilities</b> (equal to <i>item 3.32</i> )	-	-
19.19 Capital expenditure		
19.20 Depreciation		
19.21 Other non-cash expenses		

## NTA Backing

(see note 7)

20.1	Current period	Previous corresponding period
Net tangible asset backing per ordinary security	\$0.24	\$0.18

## Non-cash financing and investing activities

*Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows are as follows. If an amount is quantified, show comparative amount.*

21.1	N/A
------	-----

## International Financial Reporting Standards

*Under paragraph 39 of AASB 1: First –time Adoption of Australian Equivalents to International Financial Reporting Standards, an entity's first Australian-equivalents-to-IFRS's financial report shall include reconciliations of its equity and profit or loss under previous GAAP to its equity and profit or loss under Australian equivalents to IFRS's. See IG63 in the appendix to AASB 1 for guidance.*

22.1	N/A
------	-----

*Under paragraph 4.2 of AASB 1047: Disclosing the Impacts of Adopting Australian Equivalents to International Financial Reporting Standards, an entity must disclose any known or reliably estimable information about the impacts on the financial report had it been prepared using the Australian equivalents to IFRSs or if the aforementioned impacts are not known or reliably estimable, a statement to that effect.*

22.2	N/A
------	-----

**Comments by directors**

Comments on the following matters are required by the Exchange or, in relation to the half yearly statement, by AASB 134: Interim Financial Reporting. The comments do not take the place of the directors' report and statement (as required by the Corporations Act) but may be incorporated into the directors' report and statement. For both half yearly and preliminary final statements, if there are no comments in a section, state NIL. If there is insufficient space in comment, attach notes to this statement.

**Basis of accounts preparation**

If this statement is a half yearly statement, it is a general purpose financial report prepared in accordance with the listing rules and AASB 134: Interim Financial Reporting. It should be read in conjunction with the last annual report and any announcements to the market made by the issuer during the period. This report does not include all notes of the type normally included in an annual financial report [Delete if inapplicable.]

A description of each event since the end of the current period which has had a material effect and is not related to matters already reported, with financial effect quantified (if possible). In a half yearly report, provide explanatory comments about any seasonal or irregular factors affecting operations (*as per paragraphs 16(b), 16(b) and Aus 16.1 of AASB 134: Interim Financial Reporting*)

Beroni has announced in November 2018 that the share subscription and shareholders' agreement for the investment in Cystemix Pty Ltd, the company set up by the University of New South Wales to advance the clinical development of the anti-cancer drug PENAO would be expected to be finalised and signed in December 2018. The transaction documents have been revised a few times and are currently being reviewed by the lawyers and the other shareholders. Beroni expects these documents to be completed in April 2019.

A total of \$10 million will be invested through tranches for 40% shares in Cystemix by the end of Phase II clinical trial of PENAO. Beroni will also be granted a right to acquire a further 11% shares in Cystemix during the period commencing when 50% patient enrolment of a Phase II trial and ending within 2 months after Phase II trial completion date for \$5.5 million.

Any other factors which have affected the results in the period, or which are likely to affect results in the future, including those where the effect could not be quantified.

NIL

Franking credits available and prospects for paying fully or partly franked dividends for at least the next year

The Franking Credit balance as at 31 December 2018 was NIL

The Board will determine the ability of the Company to pay dividends in the future on an annual basis.

Changes in accounting policies, estimation methods and measurement bases since the last annual report are disclosed as follows.

*(Disclose changes in the half yearly statement in accordance with paragraph 16(a) of AASB 134: Interim Financial Reporting. Disclose changes in the preliminary final statement in accordance with paragraphs 28-29 of 108: Accounting Policies, Changes in Accounting Estimates and Errors.)*

NIL

An issuer shall explain how the transition from previous GAAP to Australian equivalents to IFRS' affected its reported financial position, financial performance and cash flows. *(as per paragraph 38 of AASB 1: First-time Adoption of Australian Equivalents to International Financial Reporting Standards)*

NIL

Revisions in estimates of amounts reported in previous periods. For half yearly reports the nature and amount of revisions in estimates of amounts reported in previous annual reports if those revisions have a material effect in this half year *(as per paragraph 16(d) of AASB 134: Interim Financial Reporting)*

NIL

Changes in contingent liabilities or assets. For half yearly reports, changes in contingent liabilities and contingent assets since the last annual report *(as per paragraph 16(j) of AASB 134: Interim Financial Reporting)*

In November 2016, Tianjin Beroni had paid US\$175,000 (about A\$250,000) to Nicobloc PLC, the UK-based supplier for the Nicobloc product, as full payment for an order. However, Nicobloc PLC had yet to deliver the goods and despite numerous follow-ups in 2017 and 2018, it has neither refunded the payment nor delivered the goods to Tianjin Beroni. In October 2018, Beroni appointed a UK-based lawyer to pursue legal action against Nicobloc PLC for a refund of the money already paid. Beroni's management is confident that it will succeed in its legal claim. Nevertheless, the company has reserved 25% of the balance i.e. US\$43,750 or A\$62,500 as a provision for the uncertainty in recovering the payment. Although the outcome of this matter cannot be predicted with certainty, management has no reason to believe that the loss of the remaining balance and the potential legal costs will have a materially adverse effect on the consolidated financial position of the Company.

In October 2018, Beroni issued 2,067,900 shares at \$1.75 to the owners of Medicine Plus as partial settlement for the acquisition of the latter company. The original settlement price of \$14.3 million agreed in June 2018 was increased by 10% to approximately \$15.8 million in October 2018 as a result of the owners of Medicine Plus agreeing to extend the settlement date to April 2019. In the event that the acquisition of Medicine Plus cannot be completed, then the shares already issued to Medicine Plus will be retained by its owners and Beroni will have to expense off these shares which have been treated as prepayment in these accounts.

The nature and amount of items affecting assets, liabilities, equity, profit or loss, or cash flows that are unusual because of their nature, size or incidence (*as per paragraph 16(c) of AASB 134: Interim Financial Reporting*)

NIL

Effect of changes in the composition of the entity during the interim period, including business combinations, acquisition or disposal of subsidiaries and long-term investments, restructurings and discontinued operations (*as per paragraph 16(i) of AASB 134: Interim Financial Reporting*)

NIL

**Annual meeting***(Preliminary final statement only)*

The annual meeting will be held as follows:

Place

Level 36 Gateway 1 Macquarie Place, Sydney NSW 2000
--

Date

To Be Determined
------------------

Time

To Be Determined
------------------

Approximate date the annual report will be available

30 April 2019
---------------

**Compliance statement**

1. This statement has been prepared under accounting policies which comply with accounting standards as defined in the *Corporations Act* or other standards acceptable to the Exchange (see note 13).

Identify other standards used

Not Applicable
----------------

2. This statement, and the financial statements under the *Corporations Act* (if separate), use the same accounting policies.

3. This statement does/does not\* (*delete one*) give a true and fair view of the matters disclosed (see note 2).

4. This statement is based on financial statements to which one of the following applies:

- ☐ The financial statements have been audited. ☐ The financial statements have been subject to review by a registered auditor (or overseas equivalent).
- ☒ The financial statements are in the process of being audited or subject to review. ☐ The financial statements have *not* yet been audited or reviewed.

5. If the accounts have been or are being audited or subject to review and the audit report is not attached, details of any qualifications are attached/will follow immediately they are available\* (*delete one*). (*Half yearly statement only - the audit report must be attached to this statement if the statement is to satisfy the requirements of the Corporations Act.*)

6. The *issuer* has/does not have\* (*delete one*) a formally constituted audit committee.

Sign here: .....

(Director and CFO)



..... Date: .....15 March 2019.....

Print name: .....Peter Wong.....